

## **AMP-activated protein kinase is a key regulator of acute neurovascular permeability**

**Silvia Dragoni<sup>1</sup>, Bruna Caridi<sup>1</sup>, Eleni Karatsai<sup>2</sup>, Thomas Burgoyne<sup>1</sup>, Mosharraf H. Sarker<sup>1,3</sup>, Patric Turowski<sup>1,4</sup>**

1. Institute of Ophthalmology, University College London, 11-43 Bath Street, London EC1V 9EL, UK.
2. NIHR Moorfields Biomedical Research Centre, Moorfields Eye Hospital, London, UK.
3. School of Science, Engineering & Design, Teesside University, Stephenson Street, Middlesbrough TS1 3BA, UK.
4. Corresponding author: [p.turowski@ucl.ac.uk](mailto:p.turowski@ucl.ac.uk)

### **KEY WORDS**

AMP-activated protein kinase; VEGF-A, bradykinin; retina; VE-cadherin; endothelial nitric oxide synthase

## SUMMARY STATEMENT

The metabolic sensor protein kinase AMPK is a key regulator of acute retinal vascular permeability by activating endothelial nitric oxide synthase and p38 MAPK.

## ABSTRACT

Many neuronal and retinal disorders are associated with pathological hyperpermeability of the microvasculature. We have used explants of rodent retinae to study acute neurovascular permeability and signal transduction and the role of AMP-activated protein kinase (AMPK). Following stimulation with either vascular endothelial growth factor (VEGF-A) or bradykinin (BK), AMPK was rapidly and strongly phosphorylated and acted as a key mediator of permeability downstream of  $Ca^{2+}$ . Accordingly, AMPK agonists potently induced acute retinal vascular leakage. AMPK activation led to phosphorylation of endothelial nitric oxide synthase (eNOS), which in turn increased VE-cadherin phosphorylation on Y685. In parallel, AMPK also mediated phosphorylation of p38 MAP kinase and HSP27, indicating that it regulated paracellular junctions and cellular contractility, both previously associated with endothelial permeability. Endothelial AMPK provided a missing link in neurovascular permeability, connecting  $Ca^{2+}$  transients to the activation of eNOS and p38, irrespective of the permeability-inducing factor used. Collectively, we find that, due to its compatibility with small molecule antagonists/agonists and siRNA, the ex-vivo retina model constitutes a reliable tool to identify and study regulators and mechanism of acute neurovascular permeability.

## INTRODUCTION

Leakage within the vascular system can be the cause or a significant co-morbidity of a variety of pathologies and is the consequence of endothelial hyperpermeability, which leads to extravasation of fluids and proteins, resulting in interstitial oedema (Nagy et al., 2008, Claesson-Welsh et al., 2020). In the nervous system, where the vasculature is uniquely impermeable and is referred to as the blood-brain barrier (BBB), vascular leakage accompanies stroke, multiple sclerosis, Parkinsons Disease as well as various forms of dementia (Turowski, 2017, Sweeney et al., 2019). Neurovascular leakage also affects the blood-retinal barrier (BRB), where it is a hallmark feature of diabetic retinopathy and neovascular age-related macular degeneration (Klaassen et al., 2013). Leakage during retinopathies is driven by permeability-inducing factors (PIFs), most prominently by the angiogenic growth factor VEGF-A; and VEGF-A antagonists are successfully used to reduce oedema and abnormal vessel growth, and restore neuronal dysfunction (Brown et al., 2013). Meta-analysis of the clinical use of anti-VEGFs in diabetic macular oedema suggests that PIFs other than VEGF-A play an important role in the pathogenesis of retinal leakage disease (Ford et al., 2013), including angiopoietin-2 (Campochiaro and Peters, 2016), lyso-phosphatidylcholine (Canning et al., 2016) and BK (Kita et al., 2015).

PIFs induce both acute and chronic vascular leakage. For instance, exposure of the vascular endothelium to VEGF-A leads to acute permeability that usually lasts less than 30 min. If not resolved persistent leakage ensues that chronically impairs vascular integrity (Nagy et al., 2008, Bates, 2010, Claesson-Welsh et al., 2020). Different PIFs bind to distinct endothelial cell (EC) surface receptors, but ultimately

all permeability responses involve paracellular junction modulation or formation of transport vesicles (Nagy et al., 2008, Turowski, 2017, Claesson-Welsh et al., 2020), suggesting that ECs regulate hyperpermeability through a core molecular machinery and common downstream signalling. Indeed, e.g.  $\text{Ca}^{2+}$  transients, phosphorylation of the MAP kinase p38 and enhanced actin contractility are associated with all vascular permeability, as is activation of eNOS (Wu et al., 1999, Hudson et al., 2014, Weidert et al., 2014, Di Lorenzo et al., 2013, Takeshi Ninchoji, 2020). Adherens and tight junction modulation is associated with paracellular permeability and the phosphorylation of VE-cadherin (VE-cad) is associated with acute permeability in the periphery and the retina (Orsenigo et al., 2012, Smith et al., 2020). In the retina the phosphorylation of occludin on S490 and its subsequent internalisation also plays an important role, at least in a more chronic setting (Murakami et al., 2012). Identifying core signalling, on which all leakage responses depend, is desirable for therapeutic development as it would allow treatment without prior knowledge of specific known (or unknown) extracellular PIF.

In the brain and the retina, entirely different signalling is induced by VEGF-A in ECs when it is added luminally (from the blood side) or abluminally (from the tissue side), with leakage-inducing signalling entirely restricted to abluminal stimulation (Hudson et al., 2014). For instance, leakage-associated p38 activation is triggered by abluminal (basal) VEGF-A stimulation, whilst activation of the PI3K/AKT pathway, which does not mediate permeability, is only seen following luminal (apical) stimulation. Thus, signalling specific to leakage can be inferred by comparing cellular stimulation following luminal and abluminal addition of VEGF-A. Conversely, BK efficiently induces permeability from the basal as well as apical side of cerebral or retinal ECs.

AMP-activated protein kinase (AMPK) is a phylogenetically conserved energy sensor that regulates energy homeostasis by coordinating metabolic pathways and thus balancing energy requirement with nutrient supply (Hardie, 2018). Previous studies suggest that AMPK acts as a protector of the BBB integrity, for instance by preventing LPS-enhanced NAD(P)H oxidase expression in ECs and the consequent barrier dysfunction and enhanced permeability (Zhao et al., 2014, Ange et al., 2020). Moreover, AMPK mediates up-regulation of BBB functions induced in vitro by metformin, a drug used for the treatment of diabetes (Takata et al., 2013). Nevertheless, in the retina AMPK activation can lead to the breakdown of the outer, non-vascular BRB, which is constituted by the retinal pigment epithelium (Villarroel et al., 2011). However, if and how AMPK contributes to permeability induction by agonists such as VEGF-A or BK in neural microvessels is unknown.

To identify and validate core components mediating acute permeability in neurovascular ECs, we adopted an ex vivo retinal preparation, originally described for rats (Warboys et al., 2009). Development of this method allowed measurement of real time changes of permeability and signalling in intact BRB vessels from rat and mouse. Importantly, this model system was compatible with precise pharmacokinetic agonist studies, parallel IHC staining and manipulation using siRNA. Our workflow can be used to identify core regulators of CNS endothelial hyperpermeability and was validated by identifying AMPK as a novel, key regulator linking VEGF-A or BK-induced  $Ca^{2+}$  transients to eNOS activation and VE-cad phosphorylation.

## RESULTS

### **VEGF-A and BK-induced permeability and junctional changes in brain microvascular ECs.**

Treatment of primary rat brain microvascular ECs with VEGF-A or BK significantly reduced TEER, indicating that paracellular permeability was induced (Figure 1A and B). TEER dropped immediately and reached a minimum within less than 5 min after addition of either VEGF-A or BK before reverting to control levels within 1 h. Thereafter, another significant, but more modest reduction in TEER was observed, indicative of a more chronic change in cell monolayer permeability. In order to correlate TEER changes with paracellular junction breakdown, the distribution of occludin and VE-Cad was analysed in VEGF-A- and BK-stimulated primary brain microvascular ECs (Figure 1C). As judged by confocal microscopy, occludin expression and distribution remained unchanged for up to 2 h of VEGF-A or BK stimulation. VE-cad levels also remained unchanged, but a broadening of the staining was observed within 5 min of the addition of the PIF, in particular at and around tricellular junctions. In agreement, cryo-immuno-EM of hCMEC/D3 cells revealed a significant relocation of VE-cad from the junctions to the cell interior by an average distance of 55 and 66 nm following a 5-min stimulation with VEGF-A and BK, respectively (Figure 1D-G). These results showed that single addition of either VEGF-A or BK induced acute and chronic permeability, and that the acute response was accompanied by VE-cad redistribution away from the junctions.

## Validation of a modified ex-vivo retinal model

In order to study the acute phase of VEGF-A- and BK-induced permeability in intact retinal microvessels in real time, we adopted an ex-vivo retinal model (Warboys et al., 2009). Permeability measurements used rat retinal explants, in which the vasculature was stabilised with a cardioplegic solution. To assess if the ex vivo preparation and perfusions led to alterations of the retinal vasculature and to determine stability of the preparation, we compared directly perfused fixed retinae with others, perfused with cardioplegic solution and left under superfusion with Krebs solution for 1 h before fixation. Subsequent whole mount staining for the tight junction protein claudin-5 and the protein VE-cad revealed characteristic strands of continuous paracellular staining (Figure 2A, B) in both preparations. Importantly, the staining pattern was indistinguishable between the two different preparations, indicating that the perfusion did not cause significant disturbances of endothelial junctions. Permeability measurements were carried out by monitoring sulforhodamine B loss from individual microvessels (Supplemental Figure 1A, B). Baseline permeability to sulforhodamine-B was very low and on average  $0.2 \pm 0.16 \times 10^{-6}$  cm/s. Taken together these data showed that morphological and barrier properties of the retinal microvasculature were well preserved in these preparations. Stimulation of the ex-vivo retina with VEGF-A or BK induced an immediate, marked loss of sulforhodamine B from the microvessel lumen, which was similar for both stimuli and amounted to a ca. 3-fold increase in microvessel permeability (Figures 2C-F). Preincubation of the ex-vivo retina with VEGFR2 inhibitor SU-1498 for 15 min prevented VEGF-A- but not BK-induced permeability, confirming the role of VEGFR2 in VEGF-A-induced permeability and indicating that BK acted through a different

receptor. Whole mount retinal staining showed that VEGF-A- and BK-induced permeability coincided with the phosphorylation of p38 on T180/Y182, its downstream effector HSP27 (on S82), as well as eNOS (on S1177) (Figure 2G, H). Phosphorylation of all three downstream effectors in response to VEGF-A but not BK was abolished following preincubation with SU-1498.

This experimental model was also used for mouse retinae. Baseline permeability in mouse preparations was  $0.15 \pm 0.1 \times 10^{-6}$  cm/s. VEGF-A stimulation increased permeability to  $0.65 \pm 0.2 \times 10^{-6}$  cm/s, and this was again sensitive to SU-1498 (Figure 2I). Furthermore, we observed SU-1498-sensitive phosphorylation of p38, HSP27 and eNOS in mouse retinal microvessels within 2 min of VEGF-A stimulation (Figure 2J). To assess the compatibility of the ex vivo retina with knockdown technology, mouse eyes were injected intravitreally with siRNA against CLDN5. Western blot analysis of retinal lysates, harvested 72 h after the injection, showed that CLDN5 expression was significantly reduced by 65% (Supplemental Figure 1C, D) and this was corroborated by whole mount staining of the retina (Supplemental Figure 1E). Microvessel permeability following knock-down of CLDN5 increased ca. 3-fold (to  $0.41 \pm 0.03$  cm/s) (Supplemental Figure 1F, G). Taken together, these results demonstrated that the ex-vivo retinal preparation was a reliable model to measure retinal paracellular microvessel permeability in rats and mice.

### **VEGF-A and Bradykinin induce AMPK phosphorylation**

In order to find new regulators of permeability, primary rat brain microvascular ECs were stimulated for 5 or 30 min with VEGF-A (50 ng/ml) from either the apical (non-permeability inducing) or basal (permeability-inducing) side (Figure 3A) and cell lysates analysed by a phospho-protein antibody array. In response to VEGF-A



stimulation many signalling components were phosphorylated, as exemplified by p38, HSP27, AMPK, eNOS, SRC, ERK and AKT (Figure 3B, C).

Differentially phosphorylated proteins were categorised into three groups; group I phosphorylated only after basal stimulation with VEGF-A (such as p38, HSP27 and AMPK), group II phosphorylated regardless of the side of the stimulation (such as eNOS, SRC and ERK) and group III phosphorylated only when VEGF-A was applied apically (such as AKT). Phosphorylation of proteins exclusively in response to basally applied VEGF-A suggested they played a role in hyperpermeability (group I). Among these, AMPK stood out as its role in acute endothelial hyperpermeability has not yet been studied in detail. Additionally, AMPK was also among the 10 proteins, for which phosphorylation increased the most in response to basally applied VEGF-A, when analysed by phospho-peptide mass spectrometry (Dragoni and Turowski, unpublished results). A previous study also demonstrates that AMPK link  $Ca^{2+}$  transients to VE-cad phosphorylation in response to ICAM-1 engagement in brain microvascular ECs (Martinelli et al., 2009).

AMPK phosphorylation in response to VEGF-A was confirmed by Western blot analysis. Stimulation of primary rat brain ECs from the basal side led to rapid, transient phosphorylation of the catalytic subunit AMPK $\alpha$  on T172, which peaked after ca. 2 min (Figure 3D). A very similar activation pattern was observed in the intact rat retina when VEGF-A was applied directly to the top of the isolated retina (corresponding to the basal side of the endothelium) (Figure 3E). BK induced similar phosphorylation of AMPK $\alpha$  T172, both in the cultured primary brain microvascular ECs and intact retina (Figure 3F, G). It was notable that AMPK phosphorylation was maximal after around 2 min in response to both VEGF-A and BK. However, BK clearly induced more sustained phosphorylation.

### **AMPK mediates VEGF-A/Bradykinin-induced permeability**

In order to specify the role of AMPK during VEGF-A- and BK-induced vascular permeability, AMPK activity was neutralised in the ex vivo retina. Preincubation of the ex-vivo retina with compound C, a widely used AMPK antagonist, significantly decreased VEGF-A- and BK- induced permeability by 80% and 93%, respectively (Figure 4A-D). Moreover, whole mount staining showed that pre-treatment with compound C prevented the VEGF-A- and BK-induced activation of p38, HSP27 and eNOS (Figures 4E, F).

Brain and retinal endothelial cells express AMPK $\alpha$ 1, but little to no  $\alpha$ 2 (Vanlandewijck et al., 2018, Lipski et al., 2020). To assess neutralisation of AMPK more specifically, AMPK $\alpha$ 1 was knocked down by intraocular injection of siRNA 72 h prior to preparing the retinae for further experimentation. Knocked-down retinae contained ca. 65% less AMPK $\alpha$ 1 (Figures 4G-H), with a substantial loss in the vasculature detectable by immunohistochemistry (Figure 4I). AMPK $\alpha$ 1 siRNA also reduced retinal AMPK $\alpha$  overall by ca. 70% (Supplemental figures 1H, I), indicating that  $\alpha$ 1 was the predominant isoform in the retina. In AMPK $\alpha$ 1 knocked-down retinae, neither VEGF-A nor BK stimulation led to significant permeability (Figures 4J-M), or the phosphorylation of p38, HSP27 or eNOS (Figure 4N).

Retinal endothelial cells express AMPK $\beta$ 1 and  $\beta$ 2 (Lipski et al., 2020) and are thus susceptible to AMPK activation by a wide variety of molecules binding to its allosteric drug and metabolite (ADaM) site (Hardie, 2017). Stimulation of ex-vivo retinae with the  $\beta$ 1 and  $\beta$ 2 -specific PF739 and MK8722 (Figure 5A-D) and the reportedly less potent,  $\beta$ 1-specific A769662 (Supplemental Figures 2A,B) led to instantaneous loss of intravascular rhodamine, with average increases of permeability of ca. 6.5, 5 and

3-fold, respectively. All three compounds also induced substantial phosphorylation of AMPK, p38, HSP27 and eNOS in retinal microvessels within 2 min of stimulation (Figure 5E, Supplemental Figure 2E). In addition, 5-aminoimidazole-4-carboxamide riboside (AICAR), a classically used compound that, once inside cells, is phosphorylated to generate an AMP analogue with some specificity for AMPK (Kim et al., 2016), led to a similar increase in permeability and phosphorylation of AMPK, p38, HSP27 and eNOS (Supplemental Figures 2C-E). Taken together these results confirmed the central role of AMPK in VEGF-A- and BK-induced acute retinal leakage and showed that AMPK acted upstream of p38 and eNOS.

### **VEGF-A- and BK-induced permeability requires Ca<sup>2+</sup> and CAMKK, p38 and eNOS**

Next, we aimed at placing AMPK within established PIF signalling cascades. Ca<sup>2+</sup> is critical for the activation of both p38 and eNOS (Takeda et al., 2004, Martinelli et al., 2009, da Silva et al., 2009). To test its role in VEGF-A-induced vascular leakage, the ex-vivo retina was incubated with BAPTA, a Ca<sup>2+</sup>chelant, prior to VEGF-A administration. BAPTA treatment significantly reduced VEGF-A-induced permeability by 94%, and also prevented the phosphorylation of p38, HSP27 and eNOS (Figures 6A, E), suggesting that Ca<sup>2+</sup> acted upstream to these molecules. CAMKK is able to phosphorylate and activate AMPK in a Ca<sup>2+</sup>-dependent manner (Martinelli et al., 2009, Hurley et al., 2005). Treatment of retinæ with the CAMKK inhibitor STO-609 significantly reduced VEGF-A-induced permeability by 86% and also prevented the activation of p38, HSP27 and eNOS (Figure 6B, E). The role of eNOS in permeability was re-confirmed by preincubation of the ex-vivo retinæ with L-NAME, which reduced VEGF-A-induced permeability by 87% but did not have any effect on p38 or

HSP27 phosphorylation (Figure 6C, E), indicating that eNOS was not upstream of p38. Finally, the ex-vivo retina was preincubated with the p38 inhibitor SB203580, which significantly reduced the VEGF-A-induced permeability by 80% as well as activation of HSP27 but not of eNOS (Figure 6D, E).

Similar results were obtained for BK-induced stimulation of retinae. BAPTA or STO nearly completely abolished BK-induced permeability, together with the activation of p38, HSP27 and eNOS (Figure 6F, G, J). Pre-treatment of the ex-vivo retina with L-NAME reduced BK-induced permeability by 67% but did not affect p38 or HSP27 phosphorylation (Figure 6H, J). Finally, SB203580 prevented BK-induced permeability as well as phosphorylation of HSP27 but not eNOS (Figure 6I, J).

Importantly, VEGF-A- or BK-induced phosphorylation of AMPK $\alpha$  was completely abolished by BAPTA or STO. VEGF-A- but not BK-induced AMPK $\alpha$  phosphorylation was also abolished by SU1498 (Figure 7A). These results indicated that in the retina, VEGF-A and BK induced Ca<sup>2+</sup> transients and consequent activation of AMPK via CAMKK. At this point signalling diverged into either activation of p38 or eNOS, which both contributed to permeability (Figure 7D).

### **VEGF-A and BK stimulate VE-Cadherin phosphorylation**

Lastly, we wanted to analyse VE-cad internalisation in the VEGF-A and BK stimulated ex vivo retina. However, systematic correlation of cryo-immuno EM to leaky microvessels proved impractical. We therefore used phosphorylation of VE-cad on Y685 as a surrogate marker for retinal microvessel permeability (Smith et al., 2020), in particular since such VE-cad phosphorylation is also a prerequisite for internalisation after BK treatment (Orsenigo et al., 2012). VEGF-A or BK stimulation of ex vivo retinae induced tyrosine phosphorylation of VE-cad on Y685 in intact

microvessels (Figure 7B). This phosphorylation was completely abolished following pre-incubation with compound C, L-NAME but not SB203580. The specific involvement of AMPK in VEGF-A- or BK-induced VE-cad phosphorylation was further confirmed in eyes injected intraocularly with AMPK $\alpha$ 1-targetting siRNA (Figure 7C). Taken together these results showed that that VE-cad modulation was downstream of AMPK/eNOS but not AMPK/p38 (Figure 7D). Indeed, direct activation of ex vivo retinae with the NO donor DEANO also induced VE-cad phosphorylation (Supplemental Figure 3A).

## DISCUSSION

Measuring retinal microvascular permeability has been mainly restricted to Miles-type assays using either fluorescent tracers or Evans Blue/albumin (Radu and Chernoff, 2013, Canning et al., 2016). Chronic leakage can also be visualised in real time by fluorescein angiography (Couturier et al., 2019). However, collectively these methods, which measure the amount of extravasated tracer, do not only reflect the degree of leakage but are also strongly influenced by dye concentration in the vasculature and dye clearance from the tissue (Nagy et al., 2008, Turowski, 2017). Further disadvantages of these methods are that compound concentrations and timing cannot be controlled accurately. Thus, they are inadequate to measure acute permeability and associated signalling accurately and in a controlled manner.

The ex-vivo retinal platform described herein addressed most of these issues. It constituted a significant advance to EC cultures, since it used a complete and intact neurovascular unit. The functionality of the retinal vasculature was preserved, with both VE-cad and claudin-5 distribution indistinguishable from that in vivo. Similar

preparations of the brain and the retina also display full cellular functionality of e.g. pericytes (Mishra et al., 2014). Importantly, permeability to sulforhodamine-B was very low and within the range of that of other small non-ionic molecules at the intact BBB in vivo (Shi et al., 2014) and notably ca. 10 x lower than in preparations of pial microvessels (Easton et al., 1997), indicating that this model was highly suitable for permeability measurement at an intact neurovascular unit. Vascular barrier properties in these retinal explants was, as expected, dependent on tight junction integrity. The reported speed, at which compounds such as VEGF-A induce permeability (Bates, 2010), was fully recapitulated. Leakage measurements were then combined with whole tissue staining and analyses of the phosphorylation status of key mediators of permeability using phospho-specific antibodies to gain mechanistic insight. Furthermore, the preparations could be interrogated using small molecule antagonists and agonists at defined concentrations and times, and allowed for the identification of key downstream regulators, common to both VEGF-A and BK stimulation. Even more specific neutralisation of key proteins was achieved through prior intraocular injection of siRNA. Conceivably this model is compatible for use with genetically modified mice and disease models, further broadening its applicability. The ex vivo platform could also be used to measure  $\text{Ca}^{2+}$  transients or localised production of reactive oxygen or nitrogen species in response to vasoactive compounds such as VEGF-A or BK.

Measurements in retinae were done ex vivo, in the absence of blood flow. Blood flow and associated shear stress may influence EC biology, such as cell-cell adhesion and inflammatory dysfunction (Orsenigo et al., 2012, Chistiakov et al., 2017, Ho et al., 2019) and their absence in our preparation must be taken into account when evaluating results. However, it should also be noted that permeability regulation by

shear stress appears to be remembered in ECs in vitro for at least 24 h (Walsh et al., 2011).

For the purpose of developing and validating the ex vivo retinal platform we have focused on PIFs, which induce permeability when added to the abluminal (tissue) side of the endothelium, such as VEGF-A and BK (Hudson et al., 2014), as these are readily applied on top of the retinal explants. Other PIFs that act only from the luminal side, such as lysophosphatidic acid (Hudson et al., 2014) or lysophosphatidylcholine (Canning et al., 2016), could also potentially be investigated in this system. However, this would require the use of a manifold injection system (Liu et al., 2000), which allows switching between injection of sulforhodamine-B with or without permeability factor into radial vessels.

VEGF-A and BK induced acute leakage in retinal microvessels, which was associated with and dependent on  $Ca^{2+}$ , the MAPK p38 and eNOS, in agreement with published data (Wu et al., 1999, Hudson et al., 2014, Di Lorenzo et al., 2013). We also identified AMPK, specifically its catalytic subunit isoform  $\alpha 1$ , as a novel key mediator of both VEGF-A- and BK-induced permeability, indicating it is a core regulator of acute vascular permeability. AMPK is primarily known to regulate energy requirements of the cell, but has also been implicated in other seemingly unrelated cellular processes such as migration, cell growth and apoptosis (Hardie, 2011). This protein kinase has been studied before in relation to its protective role of the BBB, in particular when challenged by LPS (Takata et al., 2013, Zhao et al., 2014, Ange et al., 2020), whereas in the retinal pigment epithelium it has been shown to be responsible for permeability induced by IL-1 $\beta$  (Villarroel et al., 2011). However, all these studies address chronic changes and do not focus on the role of AMPK for acute permeability. Whilst its canonical activation is dependent on cellular

AMP: ATP concentrations and phosphorylation on T172 by LKB1, we found that, in the regulation of endothelial permeability, AMPK was activated downstream of  $\text{Ca}^{2+}$  and CAMKK. This activation pathway has previously been described as non-canonical (Carling et al., 2008) and is also operational when CNS ECs facilitate the transmigration of lymphocytes (Martinelli et al., 2009). Notably, VEGF-A has also been reported before to induce NO production via a pathway requiring  $\text{Ca}^{2+}$  and AMPK (Reihill et al., 2007). Indeed, eNOS phosphorylation on S1177 can be mediated by AKT (Fulton et al., 1999) or AMPK (Martinelli et al., 2009, Youn et al., 2009). However, the PI3K/Akt pathway is not relevant for VEGF-A-induced permeability in neurovascular ECs (Hudson et al., 2014). We confirmed the phosphorylation of eNOS on S1177 downstream of AMPK both during VEGF-A and BK permeability induction. Notably, the  $\text{Ca}^{2+}$ /AMPK/eNOS pathway resulted in the phosphorylation of VE-cad on Y685, identified previously as key for vascular permeability in the periphery (Orsenigo et al., 2012) and the retina (Smith et al., 2020), thus providing a direct link between AMPK and paracellular junction regulation. Whilst in our system NO-induced VE-cad phosphorylation was sensitive to the soluble guanylyl cyclase inhibitor ODQ (Supplemental Figure 3A), suggesting a connecting role for cGMP/protein kinase G, adherens junction complexes also appear to be direct targets of NO during permeability induction, namely through S-nitrosylation of  $\beta$ -catenin and its subsequent dissociation from VE-cad (Thibeault et al., 2010). Further research is required to determine how protein kinase G and direct S-nitrosylation processes are functionally linked to the tyrosine phosphorylation and internalisation of VE-cad. For retinal permeability, occludin phosphorylation and internalisation also plays an important role. However, judging from the published time courses, it is likely to be a later event, not captured by our experiments, and



thus either secondary to VE-cad phosphorylation or, with its dependency on PKC $\beta$  activation, outside of the signalling network we have investigated here (Murakami et al., 2012).

In response to VEGF-A and BK, AMPK also regulated the phosphorylation of the MAPK p38 and its substrate HSP27, both previously implicated in actin rearrangement during endothelial barrier disruption (Sawada et al., 2015, Kasa et al., 2015, Hirano et al., 2004). P38 is a bona fide regulator of VEGF-A responses (Corre et al., 2017) and its activation downstream of cdc42 and p21-activated protein kinase (PAK) and subsequent modulation of the actin cytoskeleton occurs during VEGF-A-induced endothelial migration downstream of VEGFR2 phosphorylation on Y1214 (Lamallice et al., 2004). PAK1 also regulates VEGF-induced permeability in cultured mouse endothelial cells, possibly through direct phosphorylation of VE-cad (Gavard and Gutkind, 2006). However, in the VEGF-A- or PF739-stimulated ex vivo retina, neither permeability induction nor the phosphorylation of p38 were blocked by FRAX597, a potent group I PAK inhibitor (Han et al., 2020). This points to potentially important molecular differences between permeability regulation in neural and non-neural endothelium. In the absence of evidence for a role of PAK, we favour an alternative model of direct activation of p38 by AMPK via TAB1, a pathway described in apoptotic lymphocytes and the ischemic heart (Li et al., 2005, Lanna et al., 2014). By switching between two different p38 activation modes (Ca<sup>2+</sup>/AMPK/TAB1 versus cdc42/PAK) ECs could adapt cytoskeletal regulation to the specific requirement of EC migration or permeability. However, this model requires thorough future analysis with specific focus on all endothelially expressed PAK and TAB isoforms.

The ex-vivo retina proved to be a reliable model and demonstrated its usefulness in identifying key regulators of acute permeability. Whilst AMPK clearly emerged as

such a key regulator, it is unlikely to be exploitable as a target for anti-leakage treatments: its central role in regulating cellular energy demands throughout the body hints at many potential side effects. Activation of AMPK is currently investigated as a therapeutic option to treat cancer, metabolic syndrome and diabetes (Hardie, 2017, Kim et al., 2016). However, in light of the strong induction of permeability we observed in response to at least two AMPK agonists, we propose that these avenues should be explored cautiously, since at least acute microvascular leakage may accompany such treatment modalities. Nevertheless, our data collectively indicated that the ex vivo retina platform can play an important part in elucidating mechanisms and signalling of neurovascular leakage.

## **MATERIALS AND METHODS**

### **Materials**

Recombinant rat VEGF-A (165) was purchased from R&D Systems (Abingdon, United Kingdom). Bradykinin, Sulforhodamine-B, Evans blue, SU-1498, SB-203580, Compound-C, STO-609, L-NG-Nitro arginine methyl ester (L-NAME), BAPTA-AM, 5-Aminoimidazole-4-carboxamide ribonucleotide (AICAR), A769662, Diethylammonium (Z)-1-(N,N-diethylamino)diazen-1-ium-1,2-diolate (DEANO) and 1H-[1,2,4]Oxadiazolo[4,3-a]quinoxalin-1-one (ODQ) were purchased from MERCK (Dorset, United Kingdom). PF739 was purchased from AOBIOUS (Gloucester, USA). MK8722 was purchased from Cambridge Biosciences (Cambridge, UK). FRAX597 was purchased from Stratech Scientific Ltd (Ely, UK). Polyclonal antibodies specific for p38, HSP27, AMPK $\alpha$ , eNOS and their phosphorylated forms (p38 Thr180/Tyr182, pHSP27 Ser82, AMPK Thr172 and eNOS Ser1177) were from Cell Signaling

Technology (Beverly, MA). Recombinant Anti-AMPK alpha 1 antibody was from Abcam (Cambridge, UK). Polyclonal antibodies against phosphorylated VE-cad (p-Y658-VEC and p-Y685-VEC) were a gift from E. Dejana (Milan, Italy).

## **Animals**

Wistar female rats (7-10 weeks old) and C75BL/6J mice (7-12 weeks old) were purchased from Charles River Laboratories. All animal procedures were performed in accordance with Animal Welfare Ethical Review Body (AWERB) and Association for Research in Vision and Ophthalmology (ARVO) Statement for the Use of Animals in Ophthalmic and Vision Research guidelines and under a UK Home Office licence.

## **Methods**

### **Brain microvascular EC isolation and culture**

Microvessels were isolated from rat cortical grey matter by collagenase dispase digestion and BSA and Percoll density gradient centrifugation (Hudson et al., 2014). Purified vessels were seeded onto collagen IV/fibronectin-coated Costar Transwells (Fisher Scientific) at high density (vessels from 6 rat brains per 40 cm<sup>2</sup>). Cells were grown in EGM2-MV (Lonza), with 5 mg/ml puromycin from the second day for 3 days, for 2–3 weeks until their TEER plateaued at values above 200  $\Omega$ .cm<sup>2</sup>.

The human brain MVEC line hCMEC/D3 was also grown in EGM2-MV as previously described (Weksler B. B., 2005).

## **Transendothelial Electrical Resistance (TEER)**

Changes in the TEER were determined by time-resolved impedance spectroscopy of primary cerebral rat brain microvascular ECs grown on 12 mm Transwells, using a CellZscope (Nanoanalytics). Before the addition of VEGF-A and BK, TEER values were 500-800  $\Omega\cdot\text{cm}^2$ .

## **Immunocytochemistry**

Primary cerebral rat brain microvascular ECs were fixed with methanol ( $-20^\circ\text{C}$ ). Staining was performed as previously described using antibodies against occludin (OC-3F10, Invitrogen) (Turowski et al., 2004) or VE-cad (Martins et al., 2013).

## **Immunogold Electron Microscopy**

Cryo-immuno electron microscopy (EM) was performed as previously described (Hudson et al., 2014). Briefly, hCMEC/D3 cells were fixed in 4% PFA and 0.1% glutaraldehyde. Sections were stained using antibodies against the extracellular domain (TEA 1.31; Serotech) or the C terminus (sc-6458; Santa Cruz) of VE-cad. Image J (NIH) was used to process images and measure the distance among the gold particles and the interendothelial junctions.

## **Retinal explant preparation**

Retinal explants were prepared essentially as described before (Warboys et al., 2009). A Wistar female rats or C75BL/6J mouse was killed by overdose of  $\text{CO}_2$ . The common carotid artery was carefully exposed and cannulated with a glass microcannula. The head vasculature was then flushed first with heparinized saline

(300U/L heparin in 0.9% NaCl. Mouse: 5 ml; rat: 20 ml), then with stabilizing solution (10 mM Mg<sup>2+</sup>, 110 mM NaCl, 8 mM KCl, 10 mM HEPES, 1 mM CaCl<sub>2</sub>, pH 7.0. 10 μM Isoproterenol to be added before use. Mouse: 5 ml; rat: 20 ml), also referred to as cardioplegic solution containing isoproterenol, and finally with the same solution supplemented with 5 g/L Evans blue dye in 10% albumin (mouse: 5 ml; rat: 20 ml) for subsequent visualisation of the vasculature. Next, an eye was surgically removed and the retina isolated, together with the attached sclera. The retina was flattened onto a transparent silicone medium (SYLGARD® 184 SILICONE ELASTOMER KIT by Dow Corning), kept in position by a metal ring, and the resulting well sealed by grease. Throughout the procedure the retina was continuously superfused with Krebs solution (124 mM sodium chloride, 5 mM potassium chloride, 2 mM MgSO<sub>4</sub>, 0.125 mM NaH<sub>2</sub> PO<sub>4</sub>, 22 mM NaHCO<sub>3</sub>, 2 mM CaCl<sub>2</sub>, pH 7.4. 5 mM glucose and 0.1% BSA to be added before use).

### **Permeability measurements**

Retinal explants were mounted for visualisation and further experimentation on an upright Zeiss Axiophot fluorescent microscope. A radial vessel of a superfused retinal explant was cannulated at ca. 150 μm from the optic nerve using a microinjection needle (tip diameter 1-5 μm, sharpened to a bevel of < 30°) and the entire retinal vasculature injected with sulforhodamine-B (1 mg/ml in Krebs solution). Illumination was switched to fluorescence and the vessels were visualized under a TRITC filter using a Olympus 40X water immersion objective. For permeability measurements a microvessel was chosen at least 200 μm away from the cannulated radial vessel. Fluorescent content of the vessel was recorded continuously by time lapse (1 frame/2 s) on a Hamamatsu CCD camera for at least 2 min. A baseline was

recorded for ca. 30 s, before VEGF-A or BK (in Krebs solution) was added on the top of the retina. Time lapse series were analysed using ImageJ. Time-dependent fluorescence intensity data of the chosen vessel was derived from a square region of interest (ca. 18 x 18 pixels) (Supplemental Figure 1a and b). Fluorescence in the immediate vicinity of the microvessel was measured and subtracted from the vessel fluorescence measurements. Pixel intensity measurements were charted against time, and permeability values were computed by fitting data to the exponential equation  $C_t = C_0 * e^{-kt}$ , where  $k = 4P/d$  and  $d$  is the diameter of the vessel (Hudson et al., 2014). The difference in permeability between pre-treatment and post-treatment resulted in the absolute permeability change associated with the treatment regimen.

### **Immunohistochemistry**

After dissection, retinae from rat or mouse were fixed with 4% PFA at room temperature for 1 h. After 30 min of blocking (3% Triton X-100, 1% Tween, 0.5% Bovine Serum Albumin in 2x PBS), retinae were incubated with primary antibodies against Isolectin B4 (IB-4), P-p38, P-HSP27, P-eNOS, P-AMPK $\alpha$ , claudin-5 and P-VE-Cadherin at 4 °C o/n. Retinae were washed and incubated with matching Alexa Fluor conjugated secondary antibodies at room temperature for 2 h. Finally, retinae were washed and mounted using Mowiol 4-88 mounting medium (Sigma). More details can be found in ref (Hudson et al., 2014).

### **siRNA-mediated Knockdown of claudin-5 and AMPK $\alpha$**

Specific SiRNA sequences targeting claudin-5 or the  $\alpha$  subunit of AMPK were purchased from Dharmacon (Chicago, IL). Mice were anaesthetised by intraperitoneal injection of 100  $\mu$ l of 6% Narketan (ketamine) and 10% Dormitor (medetomidine) in

sterile water. 2  $\mu$ l of the siRNA (1ng/ml in sterile PBS) were injected intravitreally in the right eye under a stereomicroscope, using a Hamilton syringe with a 3 degrees Hamilton RN needle (Esstab). Two microliters of scrambled siRNA were injected into the left eye as a control. To inject, an initial puncture was made to the superior nasal sclera, at the level of the pars plana. Then, the tip of the needle was further introduced through the puncture hole with a 45-degree angle into the vitreous body. Retinae were isolated 72 h after the injection.

### **Phosphoantibody array**

Mature monolayers of primary, unpassaged brain microvascular ECs grown on 24 mm Costar Transwells were stimulated with VEGF-A (50 ng/ml) from the apical or basal side for 5 or 30 min. Cells from 2 Transwells were combined by lysis in 200  $\mu$ L of lysis buffer and subjected to screening using Human Phospho-Kinase Array Proteome Profiler Array (R&D Systems; ARY003B) exactly according to the manufacturer's instructions. Arrays were exposed for varying amounts of time to capture signals in the linear range and quantified by densitometric scanning and ImageJ (NIH). Signals were normalised using array-internal controls. Results were expressed as fold-differences between apical versus basal signals.

### **Western Blots**

Cell lysates were prepared as previously described(Hudson et al., 2014). Proteins were separated by SDS-PAGE and transferred to nitrocellulose by semidry electrotransfer. Membranes were blocked o/n and then incubated with the appropriate antibody diluted at 1:2,000. Membranes were washed three times with TBS/0.1% Tween-20 before 1h incubation with an anti-mouse or anti-rabbit HRP-

conjugated IgG (GE Healthcare) at a dilution of 1:10,000 and 1:5,000, respectively. Membranes were developed using the ECL reagents (Roche) and exposed to X-ray film. Protein bands were evaluated by densitometric quantification, normalized against the amount of total protein, and GAPDH or Tubulin. A selection of raw blots is shown in the supplementary information.

## **Statistics**

For each experiment a protocol was written following careful consideration of the total number of animals/samples and group sizes required to realistically achieve the objectives based on both relevant publications and previous experience of the model used. Accordingly, we performed power (0.8) calculations (<http://powerandsamplesize.com>) to determine the anticipated number of animals/samples needed. These were discussed with an in-house statistician. Generally, the statistical model used was ANOVA (pairwise, 2-sided equality). Effect size and SD were guided by our previous extensive accumulated data. We aimed to achieve a significance level of 5% and a power of 80% to minimize the number of animals per experimental group. All raw data was used for analyses. If the morphological integrity of tissue explants appeared compromised, no further experiments were performed with such samples. All attempts of replication were successful, and the data shown represents mean/aggregate data from all replications. Explants from mice or rat were randomly assigned to an experimental protocol. Each experiment on a single tissue explant consisted of a treatment and an appropriate control. Image analyses were done by different experimenters, who did not know the identity of the treatment when categorizing responses.



TEER measurements of three independent cell monolayers were combined and expressed as mean  $\pm$  SD. Significant differences were determined by two ways ANOVA with replication, with significance levels set at 0,05, followed by post-hoc Bonferroni's multiple comparison test.

Distances of VE-cad immunogold complexes were measured in electron micrographs from three independent preparations, averaged and expressed as mean  $\pm$  SD. Significant differences were determined by one-way ANOVA with significance levels set at 0.05, followed by post-hoc Dunnett's tests.

Densitometric quantification of three independent immunoblots were determined by changes in protein or phosphoprotein content normalized to tubulin or GADPH/total protein loading controls, with values expressed as fold increase. Data were presented as mean  $\pm$  SD. Statistics were performed using one-way ANOVA with significance levels set at 0.05, followed by post-hoc Dunnett's tests.

Permeability measurements from at least 3 different ex vivo retinal preparations were combined and expressed as mean  $\pm$  SD. Significant differences were determined via t-test between the control and each inhibitor.

Significance levels were set to \*,  $p < 0.05$ ; \*\*,  $0.001 < p < 0.01$ , \*\*\*,  $p \leq 0.001$ .

## ACKNOWLEDGEMENTS

We thank Dr Paul Fraser (King's College London) for introducing us to his early ex-vivo retinal preparations and Prof. John Greenwood (UCL) for critical comments on the manuscript. siRNAs targeting CLDN5 were kindly provided by Dr Matthew Campbell (Trinity College Dublin). Phospho-VE-Cad antibodies were kindly provided by Dr Fabrizio Orsenigo and Prof. Elisabetta Dejana (FIRC Institute of Molecular Oncology, Milan and Uppsala University).

This work was supported by a Moorfields Eye Charity grant to S.D. and a Diabetes UK grant to P.T.

The data that support the findings of this study are available from the corresponding author upon reasonable request.

Supplemental material for this paper can be found at the journal website:

<https://eur01.safelinks.protection.outlook.com/?url=http%3A%2F%2Fjournals.sagepub.com%2Fhome%2Fjcb&data=02%7C01%7C%7Cc27df537f41f419d715808d795e9c351%7C1faf88fea9984c5b93c9210a11d9a5c2%7C0%7C0%7C637142703553285613&sdata=J8jD0hoMtCdGE1jbrGR5QDN1QGWyjbw0hnEBOenTqj0%3D&reserved=0>

## **AUTHOR CONTRIBUTION STATEMENT**

S.D.: designed experiments; performed experiments; analysed the data; wrote the manuscript

B.C.; E.K.; T.B; M.H.S.: performed experiments

P.T.: designed experiments; performed experiments; analysed the data; wrote the manuscript

## **DISCLOSURE/CONFLICT OF INTEREST**

None.

## REFERENCES


- ANGE, M., CASTANARES-ZAPATERO, D., DE POORTERE, J., DUFEYS, C., COURTOY, G. E., BOUZIN, C., QUARCK, R., BERTRAND, L., BEAULOYE, C. & HORMAN, S. 2020. alpha1AMP-Activated Protein Kinase Protects against Lipopolysaccharide-Induced Endothelial Barrier Disruption via Junctional Reinforcement and Activation of the p38 MAPK/HSP27 Pathway. *Int J Mol Sci*, 21.
- BATES, D. O. 2010. Vascular endothelial growth factors and vascular permeability. *Cardiovasc Res*, 87, 262-71.
- BROWN, D. M., NGUYEN, Q. D., MARCUS, D. M., BOYER, D. S., PATEL, S., FEINER, L., SCHLOTTMANN, P. G., RUNDLE, A. C., ZHANG, J., RUBIO, R. G., ADAMIS, A. P., EHRLICH, J. S., HOPKINS, J. J., RIDE & GROUP, R. R. 2013. Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. *Ophthalmology*, 120, 2013-22.
- CAMPOCHIARO, P. A. & PETERS, K. G. 2016. Targeting Tie2 for Treatment of Diabetic Retinopathy and Diabetic Macular Edema. *Curr Diab Rep*, 16, 126.
- CANNING, P., KENNY, B. A., PRISE, V., GLENN, J., SARKER, M. H., HUDSON, N., BRANDT, M., LOPEZ, F. J., GALE, D., LUTHERT, P. J., ADAMSON, P., TUROWSKI, P. & STITT, A. W. 2016. Lipoprotein-associated phospholipase A2 (Lp-PLA2) as a therapeutic target to prevent retinal vasopermeability during diabetes. *Proc Natl Acad Sci U S A*, 113, 7213-8.
- CARLING, D., SANDERS, M. J. & WOODS, A. 2008. The regulation of AMP-activated protein kinase by upstream kinases. *Int J Obes (Lond)*, 32 Suppl 4, S55-9.
- CHISTIAKOV, D. A., OREKHOV, A. N. & BOBRYSEV, Y. V. 2017. Effects of shear stress on endothelial cells: go with the flow. *Acta Physiol (Oxf)*, 219, 382-408.
- CLAESSON-WELSH, L., DEJANA, E. & MCDONALD, D. M. 2020. Permeability of the Endothelial Barrier: Identifying and Reconciling Controversies. *Trends Mol Med*.
- CORRE, I., PARIS, F. & HUOT, J. 2017. The p38 pathway, a major pleiotropic cascade that transduces stress and metastatic signals in endothelial cells. *Oncotarget*, 8, 55684-55714.
- COUTURIER, A., REY, P. A., ERGINAY, A., LAVIA, C., BONNIN, S., DUPAS, B., GAUDRIC, A. & TADAYONI, R. 2019. Widefield OCT-Angiography and Fluorescein Angiography Assessments of Nonperfusion in Diabetic Retinopathy and Edema Treated with Anti-Vascular Endothelial Growth Factor. *Ophthalmology*.
- DA SILVA, C. G., SPECHT, A., WEGIEL, B., FERRAN, C. & KACZMAREK, E. 2009. Mechanism of purinergic activation of endothelial nitric oxide synthase in endothelial cells. *Circulation*, 119, 871-9.
- DI LORENZO, A., LIN, M. I., MURATA, T., LANDSKRONER-EIGER, S., SCHLEICHER, M., KOTHIYA, M., IWAKIRI, Y., YU, J., HUANG, P. L. & SESSA, W. C. 2013. eNOS-derived nitric oxide regulates endothelial barrier function through VE-cadherin and Rho GTPases. *J Cell Sci*, 126, 5541-52.
- EASTON, A. S., SARKER, M. H. & FRASER, P. A. 1997. Two components of blood-brain barrier disruption in the rat. *J Physiol*, 503 ( Pt 3), 613-23.
- FORD, J. A., LOIS, N., ROYLE, P., CLAR, C., SHYANGDAN, D. & WAUGH, N. 2013. Current treatments in diabetic macular oedema: systematic review and meta-analysis. *BMJ Open*, 3.
- FULTON, D., GRATTON, J. P., MCCABE, T. J., FONTANA, J., FUJIO, Y., WALSH, K., FRANKE, T. F., PAPAPETROPOULOS, A. & SESSA, W. C. 1999. Regulation of endothelium-derived nitric oxide production by the protein kinase Akt. *Nature*, 399, 597-601.
- GAVARD, J. & GUTKIND, J. S. 2006. VEGF controls endothelial-cell permeability by promoting the beta-arrestin-dependent endocytosis of VE-cadherin. *Nat Cell Biol*, 8, 1223-34.

- HAN, D., WANG, H., CUI, W., ZHANG, B. & CHEN, B. Z. 2020. Computational insight into the mechanisms of action and selectivity of Afraxis PAK inhibitors. *Future Med Chem*, 12, 367-385.
- HARDIE, D. G. 2011. AMP-activated protein kinase: an energy sensor that regulates all aspects of cell function. *Genes Dev*, 25, 1895-908.
- HARDIE, D. G. 2017. Targeting an energy sensor to treat diabetes. *Science*, 357, 455-456.
- HARDIE, D. G. 2018. Keeping the home fires burning: AMP-activated protein kinase. *J R Soc Interface*, 15.
- HIRANO, S., REES, R. S., YANCY, S. L., WELSH, M. J., REMICK, D. G., YAMADA, T., HATA, J. & GILMONT, R. R. 2004. Endothelial barrier dysfunction caused by LPS correlates with phosphorylation of HSP27 in vivo. *Cell Biol Toxicol*, 20, 1-14.
- HO, R. X., TAHBOUB, R., AMRAEI, R., MEYER, R. D., VARONGCHAYAKUL, N., GRINSTAFF, M. W. & RAHIMI, N. 2019. The cell adhesion molecule IGPR-1 is activated by, and regulates responses of endothelial cells to shear stress. *J Biol Chem*.
- HUDSON, N., POWNER, M. B., SARKER, M. H., BURGOYNE, T., CAMPBELL, M., OCKRIM, Z. K., MARTINELLI, R., FUTTER, C. E., GRANT, M. B., FRASER, P. A., SHIMA, D. T., GREENWOOD, J. & TUROWSKI, P. 2014. Differential apicobasal VEGF signaling at vascular blood-neural barriers. *Dev Cell*, 30, 541-52.
- HURLEY, R. L., ANDERSON, K. A., FRANZONE, J. M., KEMP, B. E., MEANS, A. R. & WITTERS, L. A. 2005. The Ca<sup>2+</sup>/calmodulin-dependent protein kinase kinases are AMP-activated protein kinase kinases. *J Biol Chem*, 280, 29060-6.
- KASA, A., CSORTOS, C. & VERIN, A. D. 2015. Cytoskeletal mechanisms regulating vascular endothelial barrier function in response to acute lung injury. *Tissue Barriers*, 3, e974448.
- KIM, J., YANG, G., KIM, Y., KIM, J. & HA, J. 2016. AMPK activators: mechanisms of action and physiological activities. *Exp Mol Med*, 48, e224.
- KITA, T., CLERMONT, A. C., MURUGESAN, N., ZHOU, Q., FUJISAWA, K., ISHIBASHI, T., AIELLO, L. P. & FEENER, E. P. 2015. Plasma Kallikrein-Kinin System as a VEGF-Independent Mediator of Diabetic Macular Edema. *Diabetes*, 64, 3588-99.
- KLAASSEN, I., VAN NOORDEN, C. J. & SCHLINGEMANN, R. O. 2013. Molecular basis of the inner blood-retinal barrier and its breakdown in diabetic macular edema and other pathological conditions. *Prog Retin Eye Res*, 34, 19-48.
- LAMALICE, L., HOULE, F., JOURDAN, G. & HUOT, J. 2004. Phosphorylation of tyrosine 1214 on VEGFR2 is required for VEGF-induced activation of Cdc42 upstream of SAPK2/p38. *Oncogene*, 23, 434-45.
- LANNA, A., HENSON, S. M., ESCORS, D. & AKBAR, A. N. 2014. The kinase p38 activated by the metabolic regulator AMPK and scaffold TAB1 drives the senescence of human T cells. *Nat Immunol*, 15, 965-72.
- LI, J., MILLER, E. J., NINOMIYA-TSUJI, J., RUSSELL, R. R., 3RD & YOUNG, L. H. 2005. AMP-activated protein kinase activates p38 mitogen-activated protein kinase by increasing recruitment of p38 MAPK to TAB1 in the ischemic heart. *Circ Res*, 97, 872-9.
- LIPSKI, D. A., FOUCART, V., DEWISPELAERE, R., CASPERS, L. E., DEFRANCE, M., BRUYNS, C. & WILLERMAIN, F. 2020. Retinal endothelial cell phenotypic modifications during experimental autoimmune uveitis: a transcriptomic approach. *BMC Ophthalmol*, 20, 106.
- LIU, B., SHAO, Y. & MIRKIN, M. V. 2000. Dual-pipet techniques for probing ionic reactions. *Anal Chem*, 72, 510-9.
- MARTINELLI, R., GEGG, M., LONGBOTTOM, R., ADAMSON, P., TUROWSKI, P. & GREENWOOD, J. 2009. ICAM-1-mediated endothelial nitric oxide synthase activation via calcium and AMP-activated protein kinase is required for transendothelial lymphocyte migration. *Mol Biol Cell*, 20, 995-1005.

- MARTINS, T., BURGOYNE, T., KENNY, B. A., HUDSON, N., FUTTER, C. E., AMBROSIO, A. F., SILVA, A. P., GREENWOOD, J. & TUROWSKI, P. 2013. Methamphetamine-induced nitric oxide promotes vesicular transport in blood-brain barrier endothelial cells. *Neuropharmacology*, 65, 74-82.
- MISHRA, A., O'FARRELL, F. M., REYNELL, C., HAMILTON, N. B., HALL, C. N. & ATTWELL, D. 2014. Imaging pericytes and capillary diameter in brain slices and isolated retinæ. *Nat Protoc*, 9, 323-36.
- MURAKAMI, T., FREY, T., LIN, C. & ANTONETTI, D. A. 2012. Protein kinase c $\beta$  phosphorylates occludin regulating tight junction trafficking in vascular endothelial growth factor-induced permeability in vivo. *Diabetes*, 61, 1573-83.
- NAGY, J. A., BENJAMIN, L., ZENG, H., DVORAK, A. M. & DVORAK, H. F. 2008. Vascular permeability, vascular hyperpermeability and angiogenesis. *Angiogenesis*, 11, 109-19.
- ORSENIKO, F., GIAMPIETRO, C., FERRARI, A., CORADA, M., GALAUP, A., SIGISMUND, S., RISTAGNO, G., MADDALUNO, L., KOH, G. Y., FRANCO, D., KURTCUOGLU, V., POULIKAKOS, D., BALUK, P., MCDONALD, D., GRAZIA LAMPUGNANI, M. & DEJANA, E. 2012. Phosphorylation of VE-cadherin is modulated by haemodynamic forces and contributes to the regulation of vascular permeability in vivo. *Nat Commun*, 3, 1208.
- RADU, M. & CHERNOFF, J. 2013. An in vivo assay to test blood vessel permeability. *J Vis Exp*, e50062.
- REIHILL, J. A., EWART, M. A., HARDIE, D. G. & SALT, I. P. 2007. AMP-activated protein kinase mediates VEGF-stimulated endothelial NO production. *Biochem Biophys Res Commun*, 354, 1084-8.
- SAWADA, J., LI, F. & KOMATSU, M. 2015. R-Ras Inhibits VEGF-Induced p38MAPK Activation and HSP27 Phosphorylation in Endothelial Cells. *J Vasc Res*, 52, 347-59.
- SHI, L., ZENG, M., SUN, Y. & FU, B. M. 2014. Quantification of blood-brain barrier solute permeability and brain transport by multiphoton microscopy. *J Biomech Eng*, 136, 031005.
- SMITH, R. O., NINCHOJI, T., GORDON, E., ANDRE, H., DEJANA, E., VESTWEBER, D., KVANTA, A. & CLAESSEON-WELSH, L. 2020. Vascular permeability in retinopathy is regulated by VEGFR2 Y949 signaling to VE-cadherin. *Elife*, 9.
- SWEENEY, M. D., ZHAO, Z., MONTAGNE, A., NELSON, A. R. & ZLOKOVIC, B. V. 2019. Blood-Brain Barrier: From Physiology to Disease and Back. *Physiol Rev*, 99, 21-78.
- TAKATA, F., DOHGU, S., MATSUMOTO, J., MACHIDA, T., KANESHIMA, S., MATSUO, M., SAKAGUCHI, S., TAKESHIGE, Y., YAMAUCHI, A. & KATAOKA, Y. 2013. Metformin induces up-regulation of blood-brain barrier functions by activating AMP-activated protein kinase in rat brain microvascular endothelial cells. *Biochem Biophys Res Commun*, 433, 586-90.
- TAKEDA, K., MATSUZAWA, A., NISHITOH, H., TOBIUME, K., KISHIDA, S., NINOMIYA-TSUJI, J., MATSUMOTO, K. & ICHIJO, H. 2004. Involvement of ASK1 in Ca<sup>2+</sup>-induced p38 MAP kinase activation. *EMBO Rep*, 5, 161-6.
- TAKESHI NINCHOJI, D. T. L., ROSS O. SMITH, MARIE HEDLUND, DIETMAR VESTWEBER, WILLIAM C. SESSA, LENA CLAESSEON-WELSH 2020. eNOS-induced vascular barrier disruption in retinopathy by c-Src activation and tyrosine phosphorylation of VE-cadherin. *bioRxiv*.
- THIBEAULT, S., RAUTUREAU, Y., OUBAHA, M., FAUBERT, D., WILKES, B. C., DELISLE, C. & GRATTON, J. P. 2010. S-nitrosylation of beta-catenin by eNOS-derived NO promotes VEGF-induced endothelial cell permeability. *Mol Cell*, 39, 468-76.
- TUROWSKI, P. 2017. Leakage at Blood-Neural Barriers. In: LINK, S. (ed.) *The Blood Brain Barrier and Inflammation*.
- TUROWSKI, P., ADAMSON, P., SATHIA, J., ZHANG, J. J., MOSS, S. E., AYLWARD, G. W., HAYES, M. J., KANUGA, N. & GREENWOOD, J. 2004. Basement membrane-dependent modification of phenotype and gene expression in human retinal pigment epithelial ARPE-19 cells. *Invest Ophthalmol Vis Sci*, 45, 2786-94.
- VANLANDEWIJCK, M., HE, L., MAE, M. A., ANDRAE, J., ANDO, K., DEL GAUDIO, F., NAHAR, K., LEBOUVIER, T., LAVINA, B., GOUVEIA, L., SUN, Y., RASCHPERGER, E., RASANEN, M., ZARB, Y.,

- MOCHIZUKI, N., KELLER, A., LENDAHL, U. & BETSHOLTZ, C. 2018. A molecular atlas of cell types and zonation in the brain vasculature. *Nature*, 554, 475-480.
- VILLARROEL, M., GARCIA-RAMIREZ, M., CORRALIZA, L., HERNANDEZ, C. & SIMO, R. 2011. Fenofibric acid prevents retinal pigment epithelium disruption induced by interleukin-1beta by suppressing AMP-activated protein kinase (AMPK) activation. *Diabetologia*, 54, 1543-53.
- WALSH, T. G., MURPHY, R. P., FITZPATRICK, P., ROCHFORD, K. D., GUINAN, A. F., MURPHY, A. & CUMMINS, P. M. 2011. Stabilization of brain microvascular endothelial barrier function by shear stress involves VE-cadherin signaling leading to modulation of pTyr-occludin levels. *J Cell Physiol*, 226, 3053-63.
- WARBOYS, C. M., TOH, H. B. & FRASER, P. A. 2009. Role of NADPH oxidase in retinal microvascular permeability increase by RAGE activation. *Invest Ophthalmol Vis Sci*, 50, 1319-28.
- WEIDERT, E., POHLER, S. E., GOMEZ, E. W. & DONG, C. 2014. Actinomyosin contraction, phosphorylation of VE-cadherin, and actin remodeling enable melanoma-induced endothelial cell-cell junction disassembly. *PLoS One*, 9, e108092.
- WEKSLER B. B., S. E. A., PERRIÈRE N., CHARNEAU P., HOLLOWAY K., LEVEQUE M., TRICOIRE-LEIGNEL H., NICOTRA A., BOURDOULOUS S, TUROWSKI P., MALE D. K., ROUX F., GREENWOOD J., ROMERO I. A., AND COURAUD P. O. 2005. Blood-brain barrier-specific properties of a human adult brain endothelial cell line. *FASEB J*, 19, 1872–1874.
- WU, H. M., YUAN, Y., ZAWIEJA, D. C., TINSLEY, J. & GRANGER, H. J. 1999. Role of phospholipase C, protein kinase C, and calcium in VEGF-induced venular hyperpermeability. *Am J Physiol*, 276, H535-42.
- YOUN, J. Y., WANG, T. & CAI, H. 2009. An ezrin/calpain/PI3K/AMPK/eNOSs1179 signaling cascade mediating VEGF-dependent endothelial nitric oxide production. *Circ Res*, 104, 50-9.
- ZHAO, Z., HU, J., GAO, X., LIANG, H. & LIU, Z. 2014. Activation of AMPK attenuates lipopolysaccharide-impaired integrity and function of blood-brain barrier in human brain microvascular endothelial cells. *Exp Mol Pathol*, 97, 386-92.


## FIGURE LEGENDS





**Figure 1. VEGF-A and BK induced permeability in cultured brain microvascular ECs.**


**(A, B)** Primary rat brain microvascular ECs were grown on permeable Transwell inserts to confluence and until they reached full electrical barrier (500-800  $\Omega$ .cm<sup>2</sup>). VEGF-A (A) or BK (B) were added at time 0. Shown are means  $\pm$  SD of normalized resistance changes (n=3). Significant changes were detected in the short- and long-term, as well as the overall responses. **(C)** Changes in the distribution of VE-Cad and Occludin in response to basal (corresponding to abluminal) stimulation with VEGF-A or BK were analysed by confocal microscopy in post-confluent primary rat brain microvascular ECs. Whites arrows indicate the broadening of the VE-Cad staining. Scale bar, 10  $\mu$ M. **(D-F)** Cryo-immuno-EM of VE-Cad distribution in control (D) and VEGF-A (E) or BK (F) stimulated human hCMEC/D3 cells. Shown are interendothelial junction areas with the two adjacent membranes (red arrowheads). White arrowheads point to gold labelled VE-Cad, which in control cells was found predominantly associated with abutting plasma membranes (within 20 nm; i.e. the distance expected by the primary and the secondary bridging Ab). Scale bar, 100 nm. **(G)** Box and whisker plot of distances of VE-Cad gold particles from cell-cell junctions as determined from three independent preparations as shown in (D-F). Individual measuring points are also shown. \*\*p < 0.01, \*\*\*p < 0.001.



**Figure 2. Validation of the ex vivo retina model in rats.**


**(A, B)** Control retinæ were from animals directly perfused fixed with 4% PFA. Ex vivo retinæ were isolated as described, flat mounted and left submerged with Krebs solutions for 1 h before PFA fixation. Whole mounts were stained for Isolectin B4 (IB4), claudin-5 (CLDN5) and VE-cad as indicated. **(C-F)** Sulforhodamine-B fluorescent intensities were recorded in single retinal capillaries. 50 ng/ml VEGF-A (C, D) or 10  $\mu$ M Bradykinin (BK) (E, F) were applied on top of the retina (abluminal side) at times indicated. Optionally retinæ were preincubated with the VEGFR2-selective antagonist SU1498 (10  $\mu$ M) for 15 min prior to recording. Independent data points and mean ( $\pm$  SD) permeability changes are shown in (D) and (F). **(G, H)** Ex vivo retinal explants were incubated with VEGF-A (G) or BK (H) for 2 min, fixed using 4% PFA and then stained using IB4 (green) and for phospho-p38 (pT180/Y182), phospho-HSP27 (pS82) or phospho-eNOS (pS1177) (magenta). **(I)** Microvessel permeability changes were recorded in mouse retinæ as described in (E, F). **(J)**

Mouse retinal explants were stimulated and stained as described in (G) using phospho-specific antibodies to p38, HSP27 and eNOS. ns non-significant, \*\*\* $p < 0.001$ . Scale bars, 10  $\mu\text{m}$ .



**Figure 3. VEGF-A and Bradykinin induced AMPK phosphorylation.**


(A-C) Primary brain microvascular ECs were stimulated with VEGF-A from the apical or basal side for 5 min triggering apically (group I), basally specific (group III) or mixed (group II) responses (see text or ref Hudson et al., 2014 for more details) (A). Cells were lysed and phosphorylation of indicated molecules assessed by phosphoantibody array analysis (B-C). (D-G) brain microvascular ECs (D, F) or ex-vivo rat retinae (E, G) were stimulated with 50 ng/ml VEGF-A (D, E) or 10  $\mu$ M BK (F, G) for the indicated length of time and AMPK $\alpha$  phosphorylation (pT172) analysed. Representative results and quantification of AMPK $\alpha$  activation from three independent experiments are shown as normalised means  $\pm$  SD. \* $p < 0.05$ , \*\* $p < 0.01$ , \*\*\* $p < 0.001$ .



**Figure 4. AMPK mediated VEGF-A/Bradykinin-induced permeability.**


(A-F) Rat ex-vivo retinæ were preincubated with or without Compound-C (CC, 10  $\mu$ M) for 15 min. 10 ng/ml VEGF-A (A, B) or 10  $\mu$ M BK (C, D) were then applied to the top of the retina and changes in permeability recorded. Alternatively (E, F), retinæ were immunostained using IB4 (green) and anti-phospho-p38, -HSP27 or -eNOS antibodies (magenta) as detailed in Figure 2. (G-N) AMPK $\alpha$ 1 specific siRNA or scrambled control was injected into the vitreous of mouse eyes. After 72 h retinæ were isolated, lysed and subjected to immunoblotting using AMPK $\alpha$ 1- and tubulin-specific antibodies (G). Shown in (H) is the densitometric quantification of 3

independent immunoblots as shown in (G). Knock-down retinæ were also prepared for ex vivo permeability measurements and stimulated using VEGF-A (50 ng/ml) (J, K) or BK (10  $\mu$ M) (L, M). Alternatively, retinæ were fixed and immunostained using IB4 (green) and anti-AMPK $\alpha$ 1 (I), phospho-p38, -HSP27 or -eNOS antibodies (magenta) (N). Note that neither PIF induced any permeability in the AMPK $\alpha$ 1 knocked-down retina. Representative results and quantifications (normalized mean  $\pm$  SD) from data points from independent experiments are shown. \*\*p < 0.01, \*\*\*p < 0.001. Scale bars, 10  $\mu$ m.



**Figure 5. Stimulation of AMPK induced permeability in the ex vivo retina.**

**(A-D)** Ex vivo preparations were stimulated with the two different AMPK activators PF739 (10  $\mu$ M) and MK8722 (10  $\mu$ M). Both agonists induced strong and immediate permeability in the ex vivo retinal microvessels. Mean ( $\pm$  SD) permeability changes recorded from three retinæ are shown in (B, D). **(E)** Ex vivo retinæ were stimulated as in (A-D) and after 2 min fixed using 4% PFA and then immunostained using IB4 (green) and or anti-phospho-p38, -HSP27 or -eNOS (magenta) as detailed in Figure 2. \* $p < 0.05$ . Scale bars, 10  $\mu$ m.




**Figure 6. VEGF-A- and Bradykinin-induced permeability requires  $\text{Ca}^{2+}$ , CaMKK, p38 and eNOS.**

(A-E) Ex vivo retinæ were preincubated with 20  $\mu\text{M}$  BAPTA ( $\text{Ca}^{2+}$  chelator) (A, E as indicated), 10  $\mu\text{M}$  STO-609 (STO, CaMKK inhibitor) (B, E as indicated), 10  $\mu\text{M}$  L-NAME (NOS inhibitor) (C, E as indicated), or 10  $\mu\text{M}$  SB202190 (SB, p38 inhibitor) (D, E as indicated) for 15 min. Then VEGF-A (50 ng/ml) was applied to the top of the




retina (abluminal side) and changes in microvessel permeability were recorded as described in Figure 2. Alternatively (E), retinæ were fixed after 2 min using 4 % PFA and then immunostained with IB4 (green) and for phosphorylation of p38, HSP27 and eNOS (magenta). **(F-J)** As in panels (A-E), except that ex vivo retinæ were stimulated with BK (10  $\mu$ M). Representative results and quantifications (independent data points and means  $\pm$  SD) are shown. \* $p < 0.05$ , \*\* $p < 0.01$ , \*\*\* $p < 0.001$ . Scale bars, 10  $\mu$ m.




**Figure 7. VEGF-A and Bradykinin induced VE-Cadherin phosphorylation.**

**(A)** Ex vivo retinae were preincubated with SU1498 (10  $\mu$ M), or BAPTA (20  $\mu$ M) or STO (10  $\mu$ M) and treated with VEGF-A and Bradykinin for 2 min. Retinae were then fixed with 4% PFA and immunostained for phospho-AMPK $\alpha$  (magenta) and with IB4 (green). **(B)** Ex vivo retinae were preincubated with compound C (10  $\mu$ M), or L-NAME (10  $\mu$ M) or SB202190 (10  $\mu$ M), treated with VEGF-A and Bradykinin for 2 min


and immunostained for phosphorylated VE-cad (using anti-pY685-VEC) (magenta) and with IB4 (green). **(C)** AMPK $\alpha$ 1 specific siRNA or scrambled control were injected into the vitreous of mouse eyes. After 72 h retinae were treated with VEGF-A and Bradykinin for 2 min and immunostained for phosphorylated VE-cad (using anti-pY685-VEC) (magenta) and with IB4 (green). **(D)** Proposed signalling networks in the ex-vivo retinal microvasculature downstream of VEGF-A and Bradykinin. Scale bars, 10  $\mu$ m.




**Figure S1. Properties of the ex vivo retina model.** (A-B) Selected frames, pseudocoloured in (B), of time-resolved recordings of a Sulforhodamine-B-filled rat capillary before and after the addition of 50 ng/ml VEGF-A, illustrating the rapid loss of fluorophore from the lumen of the vessel. The red box exemplifies a typical r.o.i used for intensity measurement. Scale bars, 10  $\mu$ m. (C-G) CLDN5 siRNA was injected into mouse eyes. 72 h later CLDN5 levels were analysed by immunoblots of retinal lysates (C-D) or by wholemount immunochemical staining (E). Scale bar, 100  $\mu$ m. Alternatively, permeability of 4 kDa Rhodamine was measured in ex vivo retinae from CLDN5 siRNA or control injected eyes (F), with quantifications (independent data points, means  $\pm$  SD) shown in (G). (H, I) AMPK $\alpha$ 1 specific siRNA or scrambled control was injected into the vitreous of mouse eyes. After 72 h retinae were isolated, lysed and subjected to immunoblotting as indicated using anti-pan-AMPK $\alpha$ -specific and -tubulin antibodies (H). Shown in (I) is the densitometric quantification of 3 independent experiments as shown in (H). \*\*p < 0.01, \*\*\*p < 0.001.



**Figure S2. Additional AMPK stimulation experiments in the ex-vivo retina. (A-D)** Ex vivo preparations were stimulated with the AMPK activators A769662 (10  $\mu$ M, A-B) and AICAR (10  $\mu$ M, C-D). Both agonists induced strong and immediate permeability in the ex vivo retinal microvessels. Mean ( $\pm$  SD) permeability changes recorded from three retiniae are shown in (B, D). **(E)** Ex vivo retiniae were stimulated as in (A-D) and after 2 min fixed using 4% PFA and then immunostained using IB4 (green) and or anti-phospho-p38, -HSP27 or -eNOS antibodies (magenta) as detailed in Figure 2. \* $p < 0.05$ . Scale bars, 10  $\mu$ m.



**Figure S3. Sensitivity of AMPK-dependent permeability signalling to inhibitors of soluble guanylyl cyclase and PAK.** (A) Ex vivo preparations were pre-incubated with or without ODQ (10  $\mu$ M) for 15 min and then stimulated with the NO donor DEANO (10  $\mu$ M). After 5 min, the ex-vivo retinae were fixed using 4% PFA and immunostained using IB4 (green) and for phospho-VE-Cad (magenta). (B, C) Ex vivo retinae were preincubated with or without FRAX597 (10  $\mu$ M) for 15 min and stimulated with the VEGF-A (10 ng/ml, B) or the AMPK activator PF739 (10  $\mu$ M, C). Shown are mean ( $\pm$  SD) permeability changes recorded from three retinae (ns, non significant). (D, E) Ex vivo retinae were stimulated with or without FRAX597 (10  $\mu$ M) for 15 min or 1h, stimulated with VEGF-A (10 ng/ml, D) or PF739 (10  $\mu$ M, E) for 5 min, fixed using 4% PFA and then immunostained using IB4 (green) and for phospho-p38 (magenta). Scale bars, 10  $\mu$ m. Note that FRAX597 was used at ca. 1000 x of the reported IC50 for PAK1-3. Other, similar ATP-binding site inhibitors used in this study, e.g. SB202190, were highly effective in the ex vivo retina at significantly lower relative inhibitory concentrations (200 x IC50), indicating that absence of FRAX597 effects were unlikely due to insufficient PAK targeting.



**Figure S4. Samples of original western blots.** To optimize our samples and save animals, we cut the membrane based on the molecular weight and we obtained stripes that we incubated with different antibodies. AMPK (60 kDa) and Tubulin (55 kDa) have a similar molecular weight. We tried to blot them together but the bands were too close (A) and to obtain nicer figures we opted for GAPDH (144 kDa) (D, E). Samples of P-AMPK (60 kDa) are shown in (B, C). Lanes 1 to 5 for all membranes: Control – 0.5 min – 2 min – 5 min – 10 min VEGF-A (10ng/ml).

## Antibodies

Anti -Phospho-AMPK $\alpha$  (Thr172) (40H9) Rabbit mAb, Cell Signaling, Product# 2535S. Citation: [https://www.citeab.com/antibodies/123532-2535-phospho-ampk-thr172-40h9-rabbit-mab?utm\\_campaign=Widget+All+Citations&utm\\_medium=Widget&utm\\_source=Cell+Signaling+Technology&utm\\_term=Cell+Signaling+Technology](https://www.citeab.com/antibodies/123532-2535-phospho-ampk-thr172-40h9-rabbit-mab?utm_campaign=Widget+All+Citations&utm_medium=Widget&utm_source=Cell+Signaling+Technology&utm_term=Cell+Signaling+Technology)

Anti-Phospho-p38 MAPK (Thr180/Tyr182) Rabbit mAb, Cell Signaling, Product# 9211S. Citation: [https://www.citeab.com/antibodies/125906-9211-phospho-p38-mapk-thr180-tyr182-antibody?utm\\_campaign=Widget+All+Citations&utm\\_medium=Widget&utm\\_source=Cell+Signaling+Technology&utm\\_term=Cell+Signaling+Technology](https://www.citeab.com/antibodies/125906-9211-phospho-p38-mapk-thr180-tyr182-antibody?utm_campaign=Widget+All+Citations&utm_medium=Widget&utm_source=Cell+Signaling+Technology&utm_term=Cell+Signaling+Technology)

Anti-Phospho-eNOS (Ser1177) (C9C3) Rabbit mAb, Cell Signaling, Product# 9570S. Citation: [https://www.citeab.com/antibodies/126250-9570-phospho-enos-ser1177-c9c3-rabbit-mab?utm\\_campaign=Widget+All+Citations&utm\\_medium=Widget&utm\\_source=Cell+Signaling+Technology&utm\\_term=Cell+Signaling+Technology](https://www.citeab.com/antibodies/126250-9570-phospho-enos-ser1177-c9c3-rabbit-mab?utm_campaign=Widget+All+Citations&utm_medium=Widget&utm_source=Cell+Signaling+Technology&utm_term=Cell+Signaling+Technology)

Anti-Phospho-HSP27 (Ser82) Antibody Rabbit mAb, Cell Signaling, Product# 2401S. Citation: [https://www.citeab.com/antibodies/123302-2401-phospho-hsp27-ser82-antibody?utm\\_campaign=Widget+All+Citations&utm\\_medium=Widget&utm\\_source=Cell+Signaling+Technology&utm\\_term=Cell+Signaling+Technology](https://www.citeab.com/antibodies/123302-2401-phospho-hsp27-ser82-antibody?utm_campaign=Widget+All+Citations&utm_medium=Widget&utm_source=Cell+Signaling+Technology&utm_term=Cell+Signaling+Technology)

Anti-AMPK $\alpha$  Rabbit mAb, Cell Signaling, Product# 2532S. Citation: [https://www.citeab.com/antibodies/123526-2532-ampk-antibody?utm\\_campaign=Widget+All+Citations&utm\\_medium=Widget&utm\\_source=Cell+Signaling+Technology&utm\\_term=Cell+Signaling+Technology](https://www.citeab.com/antibodies/123526-2532-ampk-antibody?utm_campaign=Widget+All+Citations&utm_medium=Widget&utm_source=Cell+Signaling+Technology&utm_term=Cell+Signaling+Technology)

Anti-Claudin 5 (4C3C2) Mouse mAb, ThermoFisher Scientific, Product# 35-2500. Citation: <https://www.thermofisher.com/antibody/product/Claudin-5-Antibody-clone-4C3C2-Monoclonal/35-2500>

Anti- $\alpha$ -Tubulin Mouse mAb, Merck, Product# T9026. Citation: <https://www.sigmaaldrich.com/catalog/product/sigma/t9026?lang=en&region=GB>

Anti-Phospho-Y658-VEC, produced and purified by New England Peptide. Citation: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3514492/>